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ume in one second), PEFR (peak expiratory flow rate), FEF 50% (forced expiratory flow 
at 50% of FVC), FIF50% (forced inspiratory flow at 50% of FVC), DLCO-SB (diffusing 
capacity of the lung to carbon monoxide-single breath technique), DLCO/VA (DLCO-SB/ 
alveolar ventilation ratio) or IVC (inspiratory vital capacity). 
Baseline characteristics were similar in the two groups but there were significantly more 
males and smokers in the surgical group (p < 0.01). Comparing baseline PFTs with those 
undergoing PTCA, the only significant differences were a 16.9% higher PEFR (p=0.04), a 
12.5% lower DLCONA (p=0.Ol), and a slightly lower BHT (1.9%, p=0.03) in the CABG 
group. At six months after surgery there were highly statistically significant reductions in 
FEV1, FVC, PEFR, FEF25-75%, FEF50% (all p<0.01), IVC, and DLCO-SB (p<0.03) of 
between 8 and 23% with a restrictive pattern. 
Conclusion: This study demonstrates that PTCA results in minimal disturbance of pulmo- 
nary function. It also confirms that the deleterious effects of coronary artery bypass sur- 
gery extend to six months. This post-surgical deterioration in pulmonary function should 
be taken into account when choosing between these revascularization techniques. 
1148-2 Impact of Peripheral Vascular Disease on In-Hospital 
Outcomes Following Percutaneous Coronary 
Intervention 
Babak A. Vakili, Stephen J. Green, Timothy A. Sanborn, James N. Slater, Warren 
Sherman, Kumar L. Ravi, David L. Brown, Albert Einstein College of Medicine/Montefiore 
Medical Center, Bronx, New York. 
Background: The presence of peripheral vascular disease (PVD) is associated with 
more extensive atherosclerosis and an increase in mortality from coronary heart disease. 
The impact of PVD on short-term outcomes following pemutaneous coronary intervention 
(PCI) is not well understood. 
Methods: Five hospitals in the New York City area contributed prospectively defined 
data elements on all patients undergoing PCI between January 1, 1998 and October 31, 
1999. We analyzed the effect of PVD on in-hospital outcomes following PCI using 
univadate and multivariate methods~ 
Results: Of 10,847 patients in the database, 803 (7.4%) had PVD. Patients with PVD 
were older (70 years vs. 63 years, P=O.001), more often female (34% vs. 30%, P=0.07) 
and more likely to be white (85% vs. 81%, P=O.02) than those without PVD. A history of 
diabetes (32% vs. 25%, P=0.O01 ), hypertension (81% vs. 72%, P=0.001), myocardial inf- 
arction (MI) (47% vs. 39%, P=0.001), stroke (10.3% vs. 3.1%, P=0.001), congestive 
heart failure (11.4% vs. 4.9%, P=0.001) and prior bypass surgery (23% vs. 9.8%, 
P=0.001) was more common in PVD patients. The mean ejection fraction was signifi- 
cantly reduced in PVD patients (42% vs. 45%, P=0.001) compared to those without PVD. 
Shock and hemodynamic instability was not increased in PVD patients. Left main coro- 
nary disease was more common in PVD patients (11% vs. 3.8%, P=0.001). The use of 
stents (73% vs. 82%, P=O.O01) was less common and atherectomy more common (15% 
vs. 11%, P=O.001) in PVD patients. Procedural success was 97% in both groups. Post- 
procedure complications including MI, stroke, stent thrombosis and abrupt closure did 
not differ between groups. In-hospital mortality was 1.4% among patients with PVD com- 
pared to 0.5% for those without PVD (P=0.0Ol). After adjustment for differences in clini- 
cal characteristics, the risk of in-hospital mortality for patients with PVD was 2.0 (95% 
Confidence Intervals: 1.01-4.0, P=0.04). 
Conclusion: Patients with PVD who undergo PCI are an extremely high-risk population. 
However, even after adjustment for their high-risk features, they maintain a 2-fold risk of 
in-hospital mortality. 
1148-4 Differences in Heparin Sensitivity Between Asians and 
Non-Asians 
Robert M. Minutello, Mun K. Hong, Manish Parikh, Geoffrey Bergman, Frank lacovone, 
S. Chiu Wong, New York Presbyterian Hospita/ - Come//Medical Center, New York, New 
York. 
Background: Access site bleeding complications can lengthen hospital stay and 
increase in peri-procedura[ morbidity and resource consumption. A significant proportion 
of these complications can be attributed to over-dosing of heparin. Clinical observations 
led us to hypothesize that Asians have a higher sensitivity to hepadn compared to non- 
Asians. 
Methods: In 106 patients, we prospectively administered a lower dose of hepadn to 
Asians (50 units/kg) compared to non-Asians (70 units,'kg) undergoing an elective PTCN 
stent procedure and compared peri-procedure activated clotting time (ACT) and in-hospi- 
tal bleeding. Patients with unstable angina, recent myocardial infarctions (<7 days) and 
those administered GP lib/Ilia inhibitors were excluded. 
Results: (See table.) There was no statistical difference in the baseline characteristics, 
the angiographic presence of thrombus, or the incidence of procedural complications 
between the two groups. The comparative results demonstrate that similar levels of ACT 
are achieved on average in Asians with significantly less heparin/kg. There is also a dif- 
ference in the average individual ACT to heparin/kg ratio, suggesting distinct dose 
response curves in the two groups. Using multiple linear regression, being Asian proved 
to be a significant explanatory variable in predicting ACT levels (p=.048). 
Conclusion: These findings suggest a higher sensitivity to heparin in Asians and a need 
to dose heparin lower in this population of patients. 
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1148-5 Ionic Contrast Substantially Increases the Activated 
Clot t ing  T ime in Patients Receiving Abciximab and 
Bivalirudin at the Time of Percutaneous Coronary 
Intervention 
Joel P. Reoinelli. Leslie Cho, Kent Dauterman, David Lee, A, Michael Lincoff, Cleveland 
Clinic Foundation, Cleveland, Ohio. 
Background: Ionic contrast possesses antithrombotic properties; however, the clinical 
significance of these effects remains contentious. In the setting of potent antiplatelet and 
antithrombin therapy during PCI, it remains unknown whether the use of ionic contrast 
results in a further increase in anticoagulation status. 
Methods: The first part of the ongoing REPLACE trial randomized 1056 PCI patients to 
receive either hepadn or bivalirudin as adjunctive antithrombotic therapy (the choice of 
contrast dye and glycoprotein lib/Ilia inhibition was left to the discretion of the attending 
physician). Our analysis compared the 396 available ACT values in patients who 
received ionic versus nonionic contrast, and then further stratified these patients accord- 
ing to the combination of antithrombotic and antiplatelet herapy they received. 
Results: The use of ionic contrast in PCI patients receiving adjunctive bivalirudin and 
abciximab was associated with a significant increase in the ACT (460± 189sec vs 348+ 
71sac, p=0.01 ). This additive effect of ionic contrast on ACT was not observed with other 
combinations of antithrombotic and antiplatelet herapies, (See Table) 
Conclusions: In PCI patients treated with abciximab and bivalirudin, the use of ionic 
contrast results in a significant prolongation of the ACT. This appears to represent a 
unique interaction between ionic dye, abciximab, and blvalirudin, and is not observed 
with other antiptateLet and antithrombotic ombinations. 
ACT Values (sec) 
Asian (n=55) Non-Asian (n=51) p-value 
ACT (sec) 282.4 _+ 63.5 292.9.1 _+ 48.6 0.33 
Heparin units/kg 52.4 _+ 17.2 70.0 _+ 17.8 <0.001 
ACT/Heparin units/kg 5.8 -+ 2.0 4.3 ± 0.9 <0.00t 
Ionic Nonionic P value 
Bivalirudin (all) (n=77) (n=319) NS 
395+/- 144 359+/-82 
Bivalirudin/ (n=29) (n=105) 
Abciximab 460+/-189 348+/-71 0.01 
Bivalirudin/ (n=t 9) (n=102) 
Eptifibatide 333+/-45 371+/-86 NS 
Heparin (all) (n=80) (n=322) 
288+#72 307+/-93 NS 
Hsparin/Abciximab (n=38) (n=92) 
293+/-86 286+/-106 NS 
Heparin/Eptifibatide (n=18) (n=108) 
295+/-53 317+/-94 NS 
1148-23 Frequency, Determinants, and Clinical Implications of  
Angiographically-Visible Intracoronary Thrombus 
Following Primary Angioplasty for Acute Myocardial 
Infarction 
Kishore J. Harjai, Cindy L. Grinss. Gregg W. Stone, Judith Boure, Hadsh Chandra, Mark 
Turco, Bruce Brodie, David Cox, Lorelei Gnnes, William W. O'NeilL Primary Angioplasty 
in Myocardial Infarction StudyGroup, William Beaumont Hospital, Royal Oak, Michigan. 
Background: in pts undergoing primary angioptasty (PAl for AMI, presence of intracor0- 
nary thrombus after intervention may reflect a severe prothrombotic tendency & could 
result in poor clinical OUtcome. 
Methods: In 2148 pts enrolled in PAMI-2, Stect PAMI, & PAMI No-Surgery-On-Site, we 
compared clinical & angiographic features of pts who had visible thrombus after PA (THR 
group, N=f 31) determined by core lab analysis, & those who did not. We assessed the 
impact of visible thrombus after PA on in-hospital & 1-yr outcomes in all pts & in the sub- 
set of pts with final TIMI-3 flow (N=1991). 
Results: THR pts were more likely to have Killip class > 1 (21 vs 13%) & had lower LVEF 
(46 vs 49%). They had greater diameter stenosis (94 vs 92%), & higher incidence of 
baseline thrombus (87 vs 62%) & TIMI-0 flow (75 vs 63%) in the culprit artery. During PA, 
they were less likely to receive ionic contrast (83 vs 91%) and stents (8 vs 35%), but 
more likely to receive lyrics (11 vs 5%) and ~ABP (19 vs 5%). After PA, THR pts had 
greater residual diameter stenosis (37 vs 19%), & less TIMI-3 flow (69 vs 94%) (p< 0.05 
for all). Multivariate correlates of THR after PA included presence of thrombus before PA 
& lack of stent use. During hospitalization, THR pts had similar mortality (3.8 vs 2.4%) but 
higher rate of MACE (death, reinfarction, or ischemic target vessel revascularization; 
10.7 vs 5.4%, p=O.01) than non-THR pts. During 1 yr follow-up, THR pts had higher mor- 
tality (9.2 vs 5.2%, p=0.05) but similar rate of MACE (23 vs 18%). In multivariate analy- 
ses, pt age, gender, baseline tachycardia, Killip class, LVEF, & initial TIMI flow, but not 
presence of THR after PA, were independently related to clinical outcomes. In the subset 
with final TIMI-3 flow, THR pts (n=89) had similar in-hospital death (1.1 vs 2.1%), & 
MACE (9.0 vs 5.2%), as well as 1-year death (6.1 vs 4.8%) & MACE (21 vs 17%) as non- 
THR pts (p=NS for all). 
Conclusions: 1. Visible intracoronary thrombus is uncommon after primary angioplasty, 
& is related to presence of thrombus before angioplasty & lack of stent use. 2. Post- 
angioplasty thrombus is a marker of worse in-hospital & 1-yr outcomes. However, the 
adverse prognosis of thrombus pts is related to their inferior baseline charactedstics. 
